NOD2 deletion promotes cardiac hypertrophy and fibrosis induced by pressure overload

Laboratory Investigation

Volumn 93, Issue 10, 2013, Pages 1128-1136

  Zong, Jing ^a,b   Salim, Mohamed ^a,b   Zhou, Heng ^a,b   Bian, Zhou Yan ^a,b   Dai, Jia ^a,b   Yuan, Yuan ^a,b   Deng, Wei ^a,b   Zhang, Jie Yu ^a,b   Zhang, Rui ^a,b   Wu, Qing Qing ^a,b   Tang, Qi Zhu ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

cardiac hypertrophy; fibrosis; MAPK; NF kB; NOD2; Smad; TLR4

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; SMAD PROTEIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SURGERY; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; KNOCKOUT MOUSE; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WILD TYPE;

ANIMALS; CARDIOMEGALY; CELL NUCLEUS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBROSIS; HYPERTENSION; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; NOD2 SIGNALING ADAPTOR PROTEIN; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RANDOM ALLOCATION; SMAD PROTEINS; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; UP-REGULATION;

EID: 84884898980     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.99     Document Type: Article

References (41)

1. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000;102:470-
2. Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993;22(4 Suppl A):6A-13A. (Pubitemid 23285789)
3. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002;106:3068-3
4. Maillet M, Lynch JM, Sanna B, et al. Cdc42 is an antihypertrophic molecular switch in the mouse heart. J Clin Invest 2009;119:3079-3
5. Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev 2010;90:1507-1
6. Aoyagi T, Matsui T. Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Curr Pharm Des 2011;17:1818-1
7. Balakumar P, Jagadeesh G. Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared Pharmacol Res 2010;62:365-
8. Ai W, Zhang Y, Tang QZ, et al. Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling. J Cell Biochem 2010;110:1111-1
9. Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003;3:371-
10. Chamaillard M, Girardin SE, Viala J, et al. Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Cell Microbiol 2003;5:581-
11. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004;5:800-
12. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003;278:5509-5
13. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278:8869-8
14. Abraham C, Cho JH. Functional consequences of NOD2 (CARD15) mutations. Inflamm Bowel Dis 2006;12:641-
15. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucinerich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-
16. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001;29:19-
17. Shaw MH, Reimer T, Sanchez-Valdepenas C, et al. T cell-intrinsic role of Nod2 in promoting type 1 immunity to Toxoplasma gondii. Nat Immunol 2009;10:1267-1
18. Yan L, Wei X, Tang QZ, et al. Cardiac-specific mindin overexpression attenuates cardiac hypertrophy via blocking AKT/GSK3beta and TGF-beta1-Smad signalling. Cardiovasc Res 2011;92:85-
19. Zhou H, Bian ZY, Zong J, et al. Stem cell antigen 1 protects against cardiac hypertrophy and fibrosis after pressure overload. Hypertension 2012;60:802-
20. Tsai WH, Huang DY, Yu YH, et al. Dual roles of NOD2 in TLR4-mediated signal transduction and-induced inflammatory gene expression in macrophages. Cell Microbiol 2011;13:717-
21. Yan L, Huang H, Tang QZ, et al. Breviscapine protects against cardiac hypertrophy through blocking PKC-alpha-dependent signaling. J Cell Biochem 2010;109:1158-1
22. Shen DF, Tang QZ, Yan L, et al. Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1/2 signalling. Br J Pharmacol 2010;159:970-
23. Divangahi M, Mostowy S, Coulombe F, et al. NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J Immunol 2008;181: 7157-7
24. Ferwerda G, Girardin SE, Kullberg BJ, et al. NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog 2005;1:279-
25. Body-Malapel M, Dharancy S, Berrebi D, et al. NOD2: a potential target for regulating liver injury. Lab Invest 2008;88:318-
26. El Mokhtari NE, Ott SJ, Nebel A, et al. Role of NOD2/CARD15 in coronary heart disease. BMC Genet 2007;8:
27. Selvetella G, Hirsch E, Notte A, et al. Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res 2004;63:373-
28. Chen TM, Li J, Liu L, et al. Effects of heme oxygenase-1 upregulation on blood pressure and cardiac function in an animal model of hypertensive myocardial infarction. Int J Mol Sci 2013;14:2684-2
29. Zong J, Deng W, Zhou H, et al.3,3'-Diindolylmethane protects against cardiac hypertrophy via 5'-adenosine monophosphate-activated protein kinase-alpha2. PLoS ONE 2013;8:e53
30. van Berlo JH, Elrod JW, van den Hoogenhof MM, et al. The transcription factor GATA-6 regulates pathological cardiac hypertrophy. Circ Res 2010;107:1032-1
31. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006;7:589-
32. Feldman AM, Weinberg EO, Ray PE, et al. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding Circ Res 1993;73:184-
33. Miyamoto MI, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 2000;97:793-
34. Richardson WM, Sodhi CP, Russo A, et al. Nucleotide-binding oligomerization domain-2 inhibits toll-like receptor-4 signaling in the intestinal epithelium. Gastroenterology 2010;139:904-917, 17 e1-
35. Frantz S, Kobzik L, Kim YD, et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999; 104:271-
36. Ha T, Li Y, Hua F, et al. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 2005;68:224-
37. Rohini A, Agrawal N, Koyani CN, et al. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 2010;61:269-
38. Vidal V, Dewulf J, Bahr GM. Enhanced maturation and functional capacity of monocyte-derived immature dendritic cells by the synthetic immunomodulator Murabutide. Immunology 2001;103: 479-
39. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307:731-
40. Romeo Y, Zhang X, Roux PP. Regulation and function of the RSK family of protein kinases. Biochem J 2012;441:553-
41. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010;10:415-